Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:42:44.860Z.
Calculation as of: 2026-10-06T13:42:44.860Z.
Quote observation: 2026-10-06T13:40:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0c00d818a788336e8bc85b69affa9d7057207beb35ad975aac8b5a949e44e0f4
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | $804.39M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $794.39M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $813.07M | 1.16 | 0.85 | 0.47 | 0.33 |
| AdaptHealth Corp. (AHCO)vs › | $786.39M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $823.84M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $837.98M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $790.35M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $773.03M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $768.46M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $766.35M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute